News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Madison Vaccines To Be Used In Clinical Trial Of A New Combination Approach To Immunotherapy Funded By The Prostate Cancer Foundation And The Movember Foundation


8/28/2014 12:06:20 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MADISON, Wis.--(BUSINESS WIRE)--Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company, today said its lead product candidate MVI-816 (pTVG-HP) will be used in a clinical trial testing a two-pronged immunotherapy approach to treat metastatic prostate cancer. The vaccine is intended to stimulate the immune system to fight the cancer cells while a PD-1 pathway inhibitor is designed to prevent the cancer cells from camouflaging themselves to expose the cancer cells to attack. The trial will be conducted with a $1.5 million 2014 Movember-Prostate Cancer Foundation (PCF) Challenge Award funded by the Movember Foundation and supported by the Movember-PCF Challenge Award program. The research will be conducted under the direction of Douglas McNeel, M.D., Ph.D., Professor of Medicine at the University of Wisconsin-Madison.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES